Kratom has been utilized for decades in the United States, primarily for alleviating chronic pain, anxiety, and for aiding opioid withdrawal. Despite its long-standing availability, it has largely avoided stringent regulatory oversight, which has raised concerns regarding its potential for physical dependence. Recently, interest has surged around a potent derivative known as 7-hydroxymitragynine (7-OH), which is being marketed more aggressively, although scientific research on its risks is limited.
Experts, including clinicians and addiction advocates, caution that 7-OH may have a higher addiction potential compared to traditional kratom. While there is consensus that some regulatory measures should be established, views diverge significantly on the specific mechanisms for implementing such regulations.
In July, the Drug Enforcement Agency (DEA) announced its intentions to propose that 7-OH be classified under Schedule I, the category of substances deemed most dangerous and lacking recognized medical use. This designation aims to allow for the continued sale of less potent, natural kratom products without the same restrictions imposed upon 7-OH. Marty Makary, former FDA commissioner, emphasized the necessity of regulatory action, stating the importance of being proactive in safeguarding public health, especially concerning vulnerable populations like children.
The DEA has yet to finalize these regulations, with a public commentary period concluding recently. The agency has also moved three less common kratom-related synthetic substances into Schedule I. The pressure to regulate kratom has increased following unfortunate incidents, including the deaths of students linked to kratom consumption, underscoring the urgency for regulatory action.
Addiction experts argue that classifying 7-OH as a Schedule I drug may not adequately address the issues faced by existing users, who might suffer withdrawal symptoms if access is restricted. Blanket bans could inadvertently push dependent individuals towards more dangerous substances, creating a cycle of increased harm. Furthermore, stringent regulations may hinder scientific research that is essential for understanding the full implications of these substances.
Regina LaBelle, an addiction policy expert, raised concerns about whether mere scheduling can address the underlying issues of substance use. Critics advocate for a balanced approach that includes a more rigorous regulatory marketplace to ensure safety without depriving users of access to necessary products for treatment.
Historically, kratom and its compounds like 7-OH have avoided federal regulation entirely. Some states are now beginning to implement their own measures, with varying degrees of strictness. Organizations such as Shatterproof are working with several states to create more structured policies, incorporating guidelines similar to those seen in cannabis legislation, which may include product safety, packaging, and dosing regulations. Currently, about two dozen states have adopted forms of the Kratom Consumer Protection Act, which aims to provide a baseline level of safety for kratom consumers.
Experts warn that the protection these laws offer can often be insufficient and may inadvertently favor kratom manufacturers over consumer safety. Effective regulations often require additional resources, including enforcement capabilities and independent testing for product safety.
While there are significant concerns about 7-OH's dangers, the proposal to classify it might have unusual supporters. Some experts see this as a step towards holding the market accountable and possibly fostering a safer environment for users. For instance, feedback from health professionals and public advocates indicates a mix of excitement and trepidation regarding the regulatory potential of such scheduling.
Resistant voices caution against enforcing restrictive policies too quickly, citing the risk of alienating users who rely on these substances for relief from debilitating conditions, potentially driving their consumption underground and away from necessary medical supervision. The complex reality of user experiences—ranging from severe withdrawal to successful management of opioid dependency—complicates the regulatory landscape further.
Amid these discussions, calls for further research persist. Experts stress the need to understand kratom and 7-OH thoroughly before enacting restrictive measures. The scheduling of 7-OH may inhibit studies needed to weigh its risks against benefits. Academic perspectives highlight that without proper data, drawing definitive conclusions about these substances or comparing them with other legalized psychoactive substances remains speculative at best. As new synthetic fronts in substance use emerge, ongoing conversations and research will be crucial in forging beneficial regulatory frameworks.